SAN DIEGO (AP) _ Regulus Therapeutics Inc. (RGLS) on Monday reported a loss of $8.6 million in its fourth quarter.
On a per-share basis, the San Diego-based company said it had a loss of 98 cents.
The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 91 cents per share.
The biopharmaceutical company posted revenue of $18,000 in the period.
For the year, the company reported that its loss narrowed to $48.7 million, or $5.59 per share. Revenue was nearly unchanged at $72,000.
The company's shares closed at $1.17. A year ago, they were trading at $10.08.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RGLS at https://www.zacks.com/ap/RGLS